NCT04326829招募中2 期
A Single-arm, Multi-center, Phase Ⅱ Clinical Study to Evaluate Efficacy and Safety of QL1604 Monotherapy for the Treatment of Unresectable or Metastatic Mismatch Repair Deficient (dMMR) or Microsatellite Instability-high (MSI-H) Solid Tumors That Failed to Respond to Standard Therapy
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 86
- 试验地点
- 2
- 主要终点
- ORR
研究概览
简要总结
In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Volunteer to participate in this clinical study; completely understand and know this study as well as sign the informed consent form (ICF);
- •Age ≥ 18 years and ≤ 80 years when ICF is signed;
- •Histologically confirmed locally advanced or metastatic dMMR or MSI-H status colorectal carcinoma or other malignant solid tumors;
- •At least one measureable lesion as defined per RECIST Version (v) 1.1 ;
- •Subjects who have disease progression or intolerable reactions after the currently available standard anti-cancer treatment previously received or refused prior cancer therapy regimen(s) ;
- •Subjects must provide tumor tissues and blood samples for the determination of MSI, tumor mutational burden (TMB), PD-L1 expression level;
- •Eastern Cooperative Oncology Group performance status of 0 or 1;
- •Life expectancy of greater than 12 weeks;
- •Adequate hematologic and organ function;
- •Female subjects who are not pregnant or breastfeeding
- •Male and female subjects able to have children must agree to use highly effective method of contraception throughout the study and for at least 120 days after last dose.
排除标准
- •Known hypersensitivity to any monoclonal antibody, QL1604 and/or any of its excipients;
- •Subjects with known central nervous system (CNS) metastasis;
- •Active autoimmune disease that has required systemic treatment in past 2 years, replacement therapy is acceptable;
- •Subjects with major cardiovascular and cerebrovascular diseases;
- •Subjects with uncontrollable pleural effusion, pericardial effusion or ascites;
- •Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication ≤ 14 days before the first dose of study drug;
- •Subjects who have received surgery, radiotherapy, chemotherapy, targeted therapy, other anti-tumor treatments, or participating in other clinical studies is less than 4 weeks before the first administration of investigational product;
- •Subjects who have not recovered to CTC AE Grade 1 or better from related side effects of any prior antineoplastic therapy;
- •Received a live vaccine within 30 days of planned start of study medication;
- •Infection with human immunodeficiency virus (HIV), HAV, HBV and HCV;
- •Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-ligand 1 (anti-PD-L1), anti-PD-L2 agent, cytotoxic lymphocyte associated protein-4 (CTLA-4), OX-40, CD137;
- •Known psychiatric or substance abuse disorders that would interfere with the requirements of the study;
- •History or current evidence of any condition, therapy, or laboratory abnormality, that might confound the results of the trial, or interfere with the participant's participation for the full duration of the study, or investigators/sponsor consider the subjects are not suitable for this trial.
研究组 & 干预措施
QL1604 Injection
Experimental
干预措施: QL1604 (Drug)
结局指标
主要结局
ORR
时间窗: up to 2 years
Objective response rate (assessed by independent radiological review committee (IRRC) per RECIST Version 1.1 and iRECIST)
次要结局
- ORR(up to 2 years)
- 6-month PFS rate(the proportion of subjects who have time interval over 6 months between the first dose and disease progression or death)
- 6-month OS rate(from the date of first dose until the date of 6-month)
- PFS(from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier), assessed up to 2 years)
- OS(from the date of first dose until the date of death from any cause， assessed up to 2 years)
- DOR(from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier), assessed up to 2 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction CancerEsophagogastric Junction AdenocarcinomaGastric CancerEsophageal CancerNCT00719550Amgen130
招募中
2 期
KN035 for dMMR/MSI-H Advanced Solid TumorsSolid TumorNCT036671703D Medicines (Sichuan) Co., Ltd.200
终止
2 期
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer PatientsBreast CancerNCT03795012MedSIR22
已完成
2 期
Efficacy Study of Dysport® in the Treatment of Anal Fissure.Anal FissureNCT00210444Ipsen168
招募中
不适用
Clinicopathological analysis of mismatch repair protein deficient colorectal cancer and its usefulness for identification of Lynch syndrome patientsColorectal cancerJPRN-UMIN000013814ational Cancer Center Hospital480